Important Dates

Call for Abstracts
30 Nov 2023 – 31 March 2024
Abstracts Review Process
01 April – 30 June 2024
Notification of Acceptance
01 July – 07 July 2024

The International Scientific Programme Committee invites you to contribute to the programme by submitting an abstract for possible inclusion in the 20th International Congress on Infectious Diseases (ICID) 2024.

Maximum abstract submissions per person – 5

Please follow the abstract guidelines below, to help you through the submission process.


Abstracts should be submitted under one of the following themes (click to view sub-themes):

Animal Models for infectious diseases research
Pathogenesis and Host Defenses
New Pathogen Discovery
Microbial genetics
Microbiome research

Adverse Events from antimicrobial therapy
Antibacterial Resistance
Antimicrobial Stewardship
Clinical Trials
Mechanisms of action and Spectrum
Pharmacology, PK/PD
Novel agents

Respiratory infection (excluding influenza, COVID-19 and TB)
Enteric infections
Central Nervous system infection
Bone and joint infection
Skin and soft tissue infections
Endocarditis and cardiovascular infections
Sexually transmitted infections
Urinary tract infections
Clinical case report and case series

MERS-CoV and other coronaviruses
Epidemiology and surveillance of respiratory viruses
Diagnostics and therapeutics
Vaccine and vaccination strategies

Device-related infections
Healthcare associated outbreaks
Surveillance and epidemiology
Sterilization, disinfection
The environment and infection prevention

Dengue and mosquito-borne infections
Tick-borne infections and rickettsial diseases
Clinical parasitology
Isolation, identification, diagnosis of parasites
Epidemiology of parasitic infections
Public health control

Transplant and Immunocompromised Hosts (non-HIV)
Infections Related to Travel
Infections in Displaced Populations, Refugees and Migrants
Infectious Diseases challenges in low income settings
Pediatric and Perinatal Infections

Mycology and pathogenesis
Fungal diseases epidemiology
Diagnostics in mycology
Antifungal Drugs
Anti-fungal resistance

Hepatitis A and E
Hepatitis B and D
Hepatitis C
Viral Infections (non-HIV, non-Hepatitis, non-respiratory)
Antiviral resistance

Climate change and ecological factors in infectious diseases
Education in One Health
Foodborne and Waterborne Diseases
Vector Borne Diseases and Vector Control
Zoonoses and Infections in Animals

Outbreak Modeling and Forecasting
Outbreak Preparedness
Outbreak Response and Control
Public Communication of Outbreaks and Emerging Diseases

Infectious Diseases and Artificial Intelligence
Digital Health
Big Data, Genomics and Infectious Diseases
Novel Diagnostics and Molecular Technologies (non-parasitic)

Economics, Health Policy and Implementation
Ethical Issues in Infectious Diseases
Education, training and career development
Political Factors in Disease Emergence and Response
Rumors and Misinformation in Infectious Diseases
Social Inequalities and Infectious Diseases

Epidemiology and surveillance
HIV related complication and co-infections
Antiretroviral therapy and Treatment as Prevention
HIV prophylaxis – PrEP and PEP
Ending the HIV epidemic

TB epidemiology
Tuberculosis diagnosis and treatment
Clinical research
Antimycobacterial resistance
Non-tuberculous mycobacteria
Policy & programmatic implementation in TB control

Advances in vaccine technology
Vaccine hesitancy
Vaccine safety
Efficacy and clinical trials
Vaccine immunology
Policy and regulatory affairs

Abstract Guidelines

General Information

  • All abstracts for the Congress must be submitted electronically through the electronic abstract submission system.
  • All abstracts must be submitted in English.
  • All abstracts must be received on or before 31 March 2024.
  • All abstracts have a 450-word limit of text (not including presenter information and title).
  • Abstracts must be based on original results that have not or will not be published or presented before the Congress begins on 3 December 2024.
  • Submitting authors are required to ensure that all listed co-authors have reviewed the abstract, take responsibility for its content, and agree with being listed as a co-author.
  • All potential conflicts of interest for each co-author must be provided.
  • Potential conflicts of interest include but are not limited to, commercial interest in the research and financial or in-kind support for the research from entities with a commercial interest in the research.
  • Abstract acceptance notifications will be sent by 7 July 2024.
  • Only the highest-scoring accepted abstracts will be published as an online supplement to the International Journal of Infectious Diseases (IJID)

Additional Information

  • We expect that more than 900 abstracts will be presented during the Congress. Eighty reviewers from more than 30 countries are reviewing and scoring abstracts.
  • The abstract review process is blinded, meaning that authors’ names and affiliations are not disclosed to reviewers.
  • Each abstract will be reviewed and scored by two reviewers for the quality and originality of the research, the scientific content, and the presentation.
  • A notice of acceptance or rejection will be sent to the submitting authors only. It is the responsibility of the submitting author to notify other co-authors of the Committee’s decision.
  • Session assignments will be mailed by 31 August 2024, to the address given for correspondence.
  • Acceptance of the abstract in the program and assignment to a session are determined solely by the Program Committee based on the abstract’s subject matter and combined reviewer scores and comments.
  • Decisions of the Program Committee are final.
  • Because of the logistics of assigning abstracts to sessions and the number of abstracts received, requests for particular types of presentations, sessions, days, or times will not be considered by the Program Committee.
  • Presenters of accepted abstracts must be registered and attend the Congress in order to have the abstract published in the online supplement to the International Journal of Infectious Diseases (IJID).
  • If the registration fee of the presenting author is not received by 31 August 2024 the abstract will not be published in the Final Program.
  • By submitting an abstract the author(s) agree to transfer all copyrights to ISID and to allow publication of submitted information on the ISID website, the International Journal of Infectious Diseases (IJID), or other Society related publications.
  • Instructions will be sent to the authors whose abstracts are accepted for oral or poster presentations.
  • For each abstract accepted for presentation, at least one author must attend the Congress and present the contribution.

Abstract Categories

Abstracts may be accepted into one of three categories:

Oral Presentation – Highest scoring abstracts will be selected for oral presentations.

The presenting author will be required to make a 7-minute PowerPoint presentation that concisely summarizes the research question, methods used, the results, and their significance.

Abstracts accepted for oral presentation will be published as an online supplement to the International Journal of Infectious Diseases.

Poster Presentation – The presenting author will be obliged to present the poster during the moderated poster session in Cape Town to which it has been assigned.

The highest-scoring abstracts accepted for poster presentation will be published as an online supplement to the International Journal of Infectious Diseases (IJID).

ePoster Presentation – Abstracts accepted into this category will be available for viewing and discussion on computer terminals at the Congress.

The highest-scoring abstracts accepted for electronic poster presentation will be published as an online supplement to the International Journal of Infectious Diseases (IJID).

Presenters who do not attend the session for which they have been scheduled will be ineligible to submit an abstract for the next Congress.

Those abstracts will not be published in the International Journal of Infectious Diseases.

Consider the following information according to your type of submission:

a) Research Abstracts
It is recommended that research abstracts follow the format below:

Background/Introduction: A statement of the hypothesis or research question.
Methods & Materials: An explanation of the study design and experimental method and materials used.
Results: A concise summary of the major findings of the experiment or study. Sufficient data must be provided to permit evaluation by the
reviewers and public reading of the abstract. Statements such as “additional information to be presented at the meeting” are not acceptable.
Discussion: where you comment on the results of the study, make comparisons with other studies, discuss whether more research is needed or make recommendations that could be applied in practice.
Conclusion: Summary of the overall findings and the importance of the study.

  • Abstracts that represent the presentation of investigations of compounds that involve inadequate numbers of study subjects, in vitro studies of non-representative microbiologic strains, or abstracts that lack quantitative or qualitative data will not be accepted.
  • Authors are discouraged from submitting multiple abstracts from the same project.
  • Each abstract will be judged on its own merits without reference to other submissions.
  • Repetitive abstracts will be rejected.
  • There is a limit of 5 abstracts you can submit. However, an author may present no more than two abstracts. If more than two submissions are accepted from an author, one of his/her co-authors must present any additional abstracts.
  • The presenter of any accepted abstract must be one of the co-authors listed on the original submission.
  • Please note that authors may not submit the same research; abstracts containing identical or nearly identical data from the same institution and/or individuals will be rejected.

b) Clinical Case Reports
A Case Report is a brief description of a particular condition that is unusual and also provides new insights into diagnosis or clinical management.
A Case report must make a distinct, novel contribution to the understanding of the etiologic agent, its clinical manifestations, and/or its diagnosis or treatment.
It is recommended that clinical case reports follow the format below:

Background: A statement on the particular condition that is unusual.
Case Description: A description of key features of the case. Sufficient data must be provided to permit evaluation by the reviewers and public reading of the abstract.
Discussion: A concise discussion of the distinct, novel contribution of the case to the understanding of the disease, its clinical manifestations, and/or its diagnosis or treatment.

Conclusion: Summary of the overall findings and the importance of the case report.

Case reports must be authentic, understandable, educational, and clinically interesting to an international audience of healthcare professionals, researchers, and others in all infectious diseases subspecialties. Each case report will be judged on its own merits without reference to other submissions. Repetitive case reports will be rejected.

Should you require further explanation, please send an e-mail to [email protected]

International Society for Infectious

867 Boylston Street, 5th Floor #1985
Boston, MA 02116

Phone 1+617-925-5272
Fax 1+617-865-7031
[email protected]

©2023 International Society for Infectious Diseases